Cover Image

Empowering natural killer cells to combat acute myeloid leukemia: perspective on CAR-NK Cell therapy

Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a high relapse rate and still limited therapeutic options. Natural killer (NK) cell-based immunotherapy has the potential to improve outcomes for patients with AML. Summary: Recent preclinical studies and early-sta...

Full description

Saved in:
Bibliographic Details
Main Authors: Gierschek, Fenja (Author) , Schlueter, Juliane (Author) , Kühnel, Ines (Author) , Feigl, Frederik Fabian (Author) , Schmiedel, Dominik (Author) , Prüfer, Maren (Author) , Buchinger, Leon (Author) , Cerwenka, Adelheid (Author) , Cappel, Claudia (Author) , Huenecke, Sabine (Author) , Köhl, Ulrike (Author) , Wels, Winfried S. (Author) , Ullrich, Evelyn (Author)
Format: Article (Journal)
Language:English
Published: October 1, 2024
In: Transfusion medicine and hemotherapy
Year: 2024, Pages: 1-19
ISSN:1660-3818
DOI:10.1159/000540962
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1159/000540962
Verlag, kostenfrei, Volltext: https://karger.com/tmh/article/doi/10.1159/000540962/913830/Empowering-Natural-Killer-Cells-to-Combat-Acute
Get full text
Author Notes:Fenja Gierschek, Juliane Schlueter, Ines Kühnel, Frederik Fabian Feigl, Dominik Schmiedel, Maren Prüfer, Leon Buchinger, Adelheid Cerwenka, Claudia Cappel, Sabine Huenecke, Ulrike Köhl, Winfried S. Wels, Evelyn Ullrich, on behalf of the Translational Oncology Consortium “NKfit4AML” sponsored by the German Cancer Aid
Description
Summary:Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a high relapse rate and still limited therapeutic options. Natural killer (NK) cell-based immunotherapy has the potential to improve outcomes for patients with AML. Summary: Recent preclinical studies and early-stage clinical trials aim to enhance the intrinsic anti-leukemic properties of NK cells by selectively targeting AML cells with chimeric antigen receptors (CARs). Furthermore, NK and CAR-NK cells can be combined with other therapeutic modalities or engineered further to overcome the immunosuppressive microenvironment, and treatment resistance of AML blasts and leukemia-initiating cells (LIC). Key Messages: In this review, we summarize preclinical studies with cytokine-stimulated or genetically engineered NK cells derived from different cell sources for the treatment of AML and their translation into early-phase clinical trials. We also provide an overview of promising recent developments toward innovative NK cell-based therapies that may be implemented in the near future.
Item Description:Gesehen am 07.01.2025
Physical Description:Online Resource
ISSN:1660-3818
DOI:10.1159/000540962

Similar Items